首页/数据集/Comparison of various diagnostic models for at-risk NASH vs. FAST<sup>™</sup>.

Comparison of various diagnostic models for at-risk NASH vs. FAST<sup>™</sup>.

NIAID Data Ecosystem2026-03-13 收录

数据链接：

https://figshare.com/articles/dataset/Comparison_of_various_diagnostic_models_for_at-risk_NASH_vs_FAST_sup_sup_/19605188 数据链接链接失效反馈

官方服务：

资源简介：

Comparison of various diagnostic models for at-risk NASH vs. FAST™.

应用场景：

创建时间：

2022-04-15

非酒精性脂肪性肝炎

多组学分析

Nonalcoholic steatohepatitis (NASH) is a major cause of liver fibrosis with increasing prevalence worldwide. Currently there are no approved drugs available. The development of new therapies is diffic

NIAID Data Ecosystem50

MCLR-elicited hepatic fibrosis and carcinogenic gene expression changes persist in rats with diet-induced nonalcoholic steatohepatitis through a 4-week recovery period

非酒精性脂肪性肝炎

肝脏研究

Nonalcoholic steatohepatitis (NASH) causes liver extracellular matrix (ECM) remodeling and is a risk factor for fibrosis and hepatocellular carcinoma (HCC). Microcystin-LR (MCLR) is a hepatotoxin pr

NIAID Data Ecosystem40

DataSheet3_Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice.ZIP

非酒精性脂肪性肝炎

糖尿病药物

Nonalcoholic fatty liver disease (NAFLD), which is the most common liver disease, is associated with type 2 diabetes mellitus and metabolic syndrome. Although there is no consensus on the treatment of

NIAID Data Ecosystem30

North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market

非酒精性脂肪性肝炎

医疗市场分析

North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics comes with extensive industry analysis of development components, patterns, flows, and sizes. The report calculates pres

IMR REPORTS40

Additional file 1 of Hepatoprotective effect of Qushihuayu formula on non-alcoholic steatohepatitis induced by MCD diet in rat

肝保护

非酒精性脂肪性肝炎

Additional file 1.

DataCite Commons2024-02-08 更新40